These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38403032)

  • 1. Should MMF treatment be the first-line therapy in autoimmune hepatitis?
    Alric L
    J Hepatol; 2024 Jul; 81(1):e40. PubMed ID: 38403032
    [No Abstract]   [Full Text] [Related]  

  • 2. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply to: Comments on "An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis".
    Snijders RJALM; Stoelinga AEC; van Hoek B; Drenth JPH
    J Hepatol; 2024 Jul; 81(1):e43-e44. PubMed ID: 38554845
    [No Abstract]   [Full Text] [Related]  

  • 4. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.
    Devlin SM; Swain MG; Urbanski SJ; Burak KW
    Can J Gastroenterol; 2004 May; 18(5):321-6. PubMed ID: 15152283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil--a new treatment for autoimmune hepatitis?
    Dhawan A; Mieli-Vergani G
    J Hepatol; 2000 Sep; 33(3):480-1. PubMed ID: 11020006
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis: new hope for difficult cases of autoimmune hepatitis.
    Halac U; Alvarez F
    Nat Rev Gastroenterol Hepatol; 2009 Nov; 6(11):629-30. PubMed ID: 19881512
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of mycophenolate in the treatment of autoimmune hepatitis.
    Oo YH; Neuberger J
    Liver Int; 2005 Aug; 25(4):687-91. PubMed ID: 15998416
    [No Abstract]   [Full Text] [Related]  

  • 10. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
    Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
    Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
    Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
    Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Schramm C; Lohse AW
    J Hepatol; 2011 Sep; 55(3):510-511. PubMed ID: 21281682
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree.
    Czaja AJ
    J Hepatol; 2009 Jul; 51(1):8-10. PubMed ID: 19446910
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis.
    Santiago P; Schwartz I; Tamariz L; Levy C
    Aliment Pharmacol Ther; 2019 Apr; 49(7):830-839. PubMed ID: 30761563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.
    Sharzehi K; Huang MA; Schreibman IR; Brown KA
    Can J Gastroenterol; 2010 Oct; 24(10):588-92. PubMed ID: 21037986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
    Fan X; Yang F; Zhou L; Yang L
    J Hepatol; 2024 Jul; 81(1):e35-e36. PubMed ID: 38307344
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.